Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
1936 articles with Gilead Sciences, Inc.
-
Top 12 Biotech Companies Hiring Now
12/7/2021
Life sciences professionals are mixed as to whether the job market is in favor of the candidate or the employer. However, life sciences employers aren’t. -
The news comes just three weeks after Merck paused its Phase II IMAGINE-DR trial, which was studying a combination of islatravir with MK-8507.
-
Early tests of Regeneron’s antibody cocktail show it isn’t as effective against Omicron while a separate tests of Eli Lilly’s antibody cocktail also demonstrated the same.
-
Gilead’s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS
11/29/2021
Gilead Sciences, Inc. (Nasdaq: GILD) will present additional data from the Phase 3 ASCENT study of Trodelvy® (sacituzumab govitecan-hziy) during the upcoming San Antonio Breast Cancer Symposium (SABCS) being held from December 7-10.
-
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
-
Both Gilead Sciences and Merck announced they were pausing a Phase II trial of islatravir and lenacapavir in HIV.
-
Trodelvy® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line
11/23/2021
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy®.
-
“I hope to thread the needle between pricing responsibly and achieving profitability," Jarrett said.
-
Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta
11/19/2021
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for bulevirtide for injection (2 mg).
-
Gilead Sciences to Present at Upcoming Investor Conference - Nov 18, 2021
11/18/2021
Gilead Sciences, Inc. announced that its executives will be speaking at the following investor conference.
-
Gilead Exercises Options to Three Arcus Biosciences Clinical-stage Programs and Adds Research Collaboration
11/18/2021
Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced that Gilead has exercised its options to three programs in Arcus’s clinical-stage portfolio, including both anti-TIGIT molecules, domvanalimab and AB308, as well as etrumadenant and quemliclustat.
-
Gilead Sciences announced it exercised its options to three of Arcus Biosciences’ programs. Two are anti-TIGIT molecules, domvanalimab and AB308, and the other is etrumadenant and quemliclustat.
-
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint
11/11/2021
Everest Medicines and Gilead Sciences, Inc. jointly announces that Everest Medicines' Phase 2b EVER-132-001 study of sacituzumab govitecan met its primary endpoint of overall response rate in metastatic triple-negative breast cancer.
-
Gilead to Present Data From Liver Disease Development Programs at The Liver Meeting®
11/9/2021
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new clinical and real-world data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place from November 12-15.
-
Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline
11/4/2021
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite today announced that data at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition (December 11-14)
-
Vaccinations will be required by January 4 under the new White House plan.
-
BlueSphere Bio aims to overcome challenges in the CAR T space with a precision approach to T cell therapy.
-
Shoreline Biosciences secured $140 million in financing to accelerate the growth of its induced pluripotent stem cells (iPSC)-based immunotherapies and support the expansion of its manufacturing capabilities.
-
Clinical Catch-Up: October 25-29
11/1/2021
Yet another busy week for clinical trial news. Here’s a look. -
Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting
10/29/2021
Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy ® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting